TRIM39-RPP21

Across TCGA pan-cancer cohorts, TRIM39-RPP21 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated TRIM39-RPP21 data layer compared with 17 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher TRIM39-RPP21 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TRIM39-RPP21 expression acts as an unfavorable survival marker.

LIHC and PRAD are the cancer types where TRIM39-RPP21 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.156	0.777	.003	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

TRIM39-RPP21–LIHC (OS)

Open the LIHC breakdown →